Depemokimab is an anti-interleukin-5 agent that can be administered every six months, offering a less frequent dosing alternative.
In a phase 3 study, 629 patients 12 and older participated, including 419 who had previously received depemokimab and 210 who had taken a placebo in an earlier trial.
After 52 weeks of treatment, annualized exacerbation rates were 0.46 for those who had previously used depemokimab and 0.48 for those transitioning from a placebo. Overall, 72% of patients were exacerbation free and 96% did not require hospitalization or emergency department visits.
GSK has submitted depemokimab for FDA approval.
